Diagnostic Innovation Reimagined

Progress in patient care begins with precision. Renew advances NGS-based tools and assays to measure biology more precisely, enabling more accurate and actionable clinical testing.

• Our Foundation

[part 01]

We bring together scientific and operational capabilities to move impactful ideas from early biological signal to clinical practice. Renew's integrated ecosystem is designed to support translation at every stage.

• operating companies & programs

Where Innovation Happens

[learn more]

A high-throughput clinical and research laboratory that supplies the sequencing, assay development, and operational backbone for Renew’s diagnostic innovation. This infrastructure supports the scale of translational programs and partnerships from early development to clinical application.

[learn more]

A biotechnology company developing neurodegenerative-focused liquid biopsy tests for earlier, more precise clinical insight, expanding the clinical foundation for Renew’s diagnostic development programs.

• Ecosystem Advantages

Advanced Sequencing And Bioinformatics

A distinct sequencing and bioinformatics stack built on native-read and proprietary technologies, broadening high-resolution insight beyond predefined regions and questions

Assay And Product Development

An integrated assay and product development environment that translates biological insight into targeted, deployable applications.

Study Design and Translational Strategy

An approach supported by established academic and clinical partnerships, with access to well-characterized samples that enable evidence to hold up through validation and clinical use.

Regulatory, Operations, & Commercialization

A shared operational foundation with centralized infrastructure and validated systems, enabling programs to stand up quickly and scale with confidence.

What We're
Delivering

Renew translates innovation into real-world impact through active clinical and research programs, acquired technologies, and strategic partnerships that advance development capabilities and accelerate commercialization

100+ Client Projects Completed

Wasatch BioLabs completed 100+ research projects its first 18 months across biomarker discovery, assay development, and clinical validation.

Renew Acquires 7 Technologies Through SRA

Covering neurodegeneration, women’s health, Lyme disease, and cardiovascular disease, including laboratory devices and assay development tools.

07

3 Major Partnerships Established In 2025

Renew's subsidiaries partner with ONT, Agilent, and KU ADRC to advance core technology development and access.

We're translating innovation into real-world capability through active clinical and research programs, acquired technologies, and strategic partnerships that expand development capabilities and accelerate commercial impact.

In The Press

(01)

Wasatch BioLabs Partners
With Agilent Technologies

The collaboration brings together Agilent's enrichment chemistries—SureSelect for genomic DNA and Avida for cell-free DNA—and WBL's proprietary Oxford Nanopore-based native-read workflow.

learn more

(02)

Forging a Path Toward Early AD Detection

Through a collaboration between BYU and KU ADRC, 775 longitudinal patient samples will be analyzed using Resonant’s technology to evaluate its potential for early detection of Alzheimer’s disease.

learn more

(03)

Wasatch BioLabs And Oxford Nanopore Team Up

"Together we will co-develop products that will replace conventional technologies and reshape how methylation is incorporated into clinical research and diagnostics" - Kathleen Barnes, SVP of Precision Medicine at ONT

learn more

Resources

HomepageTechnologiesOur TeamContact Us↗

Subscribe

Thank you!
Oops! Something went wrong.
2315 W 700 S Suite R,Pleasant Grove, UT 84062